



# SmartPA Criteria Proposal

<b>Drug/Drug Class:</b>	Oxazolidinone Fiscal Edit
<b>First Implementation Date:</b>	October 28, 2021
<b>Revised Date:</b>	May 11, 2023
<b>Prepared for:</b>	MO HealthNet
<b>Prepared by:</b>	MO HealthNet/Conduent
<b>Criteria Status:</b>	<input checked="" type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

## Executive Summary

**Purpose:** Ensure appropriate utilization and control of oral oxazolidinone agents

**Why Issue Selected:** Oxazolidinones are a class of antibiotics with strong activity against Gram-positive bacteria, including methicillin-resistant *Staphylococcus aureus* and vancomycin-resistant enterococci. Oxazolidinones exhibit their antibacterial effects by inhibiting protein synthesis through binding to the 50S subunit of the bacterial ribosome. At this time, there are two FDA approved oxazolidinone agents: Zyvox® (linezolid), approved in 2000, and Sivextro® (tedizolid phosphate), approved in 2014. Generic versions of Zyvox are now available. It is fiscally advantageous for MO HealthNet to establish guidelines for therapy with oral oxazolidinone agents.

Program-Specific Information:	Date Range FFS 10-1-2021 to 9-31-2022			
	Drug	Claims	Spend	Avg Spend per Claim
	LINEZOLID 100 MG/5 ML SUSP	13	\$11,831.15	\$910.09
	LINEZOLID 600 MG TABLET	682	\$34,081.02	\$49.97
	SIVEXTRO 200 MG TABLET	9	\$73,339.94	\$8,148.88

**Type of Criteria:**  Increased risk of ADE  Preferred Drug List  
 Appropriate Indications  Clinical Edit

**Data Sources:**  Only Administrative Databases  Databases + Prescriber-Supplied

## Setting & Population

- Drug class for review: Oral Oxazolidinone agents
- Age range: All appropriate MO HealthNet participants

## Approval Criteria

- Claim is for linezolid **OR**
- Clinical consultant review required for therapy with Sivextro (tedizolid phosphate)

## Denial Criteria

- Therapy will be denied if all approval criteria are not met

## Required Documentation

Laboratory Results:  
MedWatch Form:


Progress Notes:  
Other:

X

## Disposition of Edit

Denial: Exception code "0683" (Fiscal Edit)  
Rule Type: CE

## Default Approval Period

1 month

## References

- Zyvox® (linezolid) [package insert]. New York, NY: Pharmacia & Upjohn Co, Division of Pfizer Inc; April 2021.
- Sivextro® (tedizolid phosphate) [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.; October 2020.
- Roger C, Roberts JA, Muller L. Clinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones. Clin Pharmacokinet 2018; 57:559.